We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · July 27, 2020

Prolonged Survival in Patients With HR+/HER2− MBC Treated With Initial Endocrine Therapy

British Journal of Cancer


Additional Info

British Journal of Cancer
Survival in Patients With HR+/HER2− Metastatic Breast Cancer Treated With Initial Endocrine Therapy Versus Initial Chemotherapy. A French Population-Based Study
Br. J. Cancer 2020 Jul 17;[EPub Ahead of Print], J Simon, M Chaix, O Billa, AM Kamga, P Roignot, S Ladoire, C Coutant, P Arveux, C Quantin, TS Dabakuyo-Yonli

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading